Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage II, III, or IV diffuse large cell lymphoma and WHO variants~  * CD20+ large B-cell lymphoma, including those with immunoblastic features~ * CD20+ thymic B-cell lymphoma~ * No evidence of indolent lymphoma~ * No mantle cell lymphomas or equivocal B-cell lymphomas that express markers of mantle cell lymphoma (e.g., cyclin D) or other subtypes~* No known lymphomatous involvement of the CNS, including the parenchyma or leptomeninges~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* CALGB 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count at least 1,000/mm3\*~* Platelet count at least 100,000/mm3\* NOTE: \* Unless due to lymphoma~Hepatic:~* Bilirubin no greater than 2.0 mg/dL\* NOTE: \* Unless due to lymphoma or Gilbert's disease~Renal:~* Creatinine no greater than 1.5 mg/dL\* NOTE: \* Unless due to lymphoma~Cardiovascular:~* LVEF greater than 45%~* No ischemic heart disease~* No myocardial infarction or congestive heart failure within the past year~Other:~* HIV negative~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior cytotoxic chemotherapy~* No other concurrent chemotherapy~Endocrine therapy:~* Prior short-course of glucocorticoids allowed~* No concurrent hormones except for non-disease-related conditions (e.g., insulin for diabetes)~* No concurrent steroids except for adrenal failure~* No concurrent dexamethasone or other steroidal antiemetics~Radiotherapy:~* Prior limited-field radiotherapy allowed~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EPOCH-Rituximab (Type: EXPERIMENTAL): Addition of monoclonal antibody therapy to chemotherapy for treatment of pts with aggressive CD20+ NHL

Based on this trial design, predict the completion outcome and termination type (if applicable).